Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.86 |
| ▸ | CLK2 | P49760 | 9/20 | 0.75 |
| ▸ | CLK3 | P49761 | 9/20 | 0.75 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.75 |
| ▸ | WNT1 | P04628 | 11/20 | 0.72 |
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17575954 | 0.93 | CLK2 (0.75) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17556388 | 0.92 | TGFBR1 (1.00) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17575908 | 0.92 | TGFBR1 (0.73) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17575923 | 0.91 | CLK2 (0.73) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17555529 | 0.91 | WNT1 (0.86) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17576015 | 0.91 | WNT1 (0.74) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17575915 | 0.91 | TGFBR1 (0.71) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17555518 | 0.91 | WNT1 (0.86) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17555655 | 0.90 | TGFBR1 (0.84) | TGFBR1CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17555499 | 0.90 | CLK2 (0.82) | TGFBR1CLK2CLK3DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10052331-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-08-21 | — | — | US | claimed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | claimed |
| US-9763951-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | claimed |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2017-08-03 | — | — | US | claimed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | claimed |
| WO-2016040188-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2016-03-17 | — | — | WO | claimed |
| US-10052331-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | disclosed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | disclosed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | disclosed |
| US-9763951-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763951-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763951-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| WO-2016040188-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | TGFBR1 517/4885CLK2 2336/4885CLK3 1835/4885 |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | TGFBR1 517/4885CLK2 2336/4885CLK3 1835/4885 |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | TGFBR1 517/4885CLK2 2336/4885CLK3 1835/4885 |
| US-10052331-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | WNT3, WNT1, WNT3A | TGFBR1 517/4885CLK2 2336/4885CLK3 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.